A new antibiotic targeted at Clostridium difficile has won unanimous support from a government medical panel convened by the U.S. Food and Drug Administration.
C. difficile is a particular scourge among hospitals and long-term care facilities. The antibiotic, called DIFICID™ (fidaxomicin), is manufactured by Optimer Pharmaceuticals. If approved, DIFICID would be the only antibiotic besides vancomycin to be FDA-approved for the treatment of C. difficile. Research from the manufacturer reportedly showed it is better at preventing recurrences of the disease.
From the May 01, 2011 Issue of McKnight's Long-Term Care News